EverCross™ AB35W05080135 (UDI 00763000184209)Recalls & reported problems
Ev3, Inc · PTA AB35W05080135 EVERCROSS 035 V09 · Class 2
- Adverse event reports
- 3
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 00763000184209), received between Oct 1, 2020 and Feb 19, 2025 — classified as 3 malfunctions.
The most frequently reported specific device problem is “Burst Container or Vessel” (2 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.
Reports received per month
Most reported problems
Device problems
- Burst Container or Vessel2
- Positioning Problem2
- Deflation Problem1
Patient problems
- No Clinical Signs, Symptoms or Conditions3
- No Consequences Or Impact To Patient2
Recent adverse event reports
The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.
MalfunctionFeb 19, 2025Deflation Problem; Deflation Problem
IT WAS REPORTED THAT DURING A PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY PROCEDURE USING THE EVERCROSS PTA BALLOON CATHETER, THERE WERE DEFLATION DIFFICULTIES. THE BALLOON TOOK 10 MINUTES TO FULLY DEFLATE FOR REMOVAL FROM THE POPLITEAL ARTERY. THE LESION WAS LOCATED IN THE MID-SECTION OF THE PERIPHERAL ARTERY WITH A LENGTH OF 60MM AND A DIAMETER OF 5MM, WITH MINIMAL TORTUOSITY AND CALCIFICATION. THE VESSEL WAS POST-DILATED, AND THE BALLOON WAS INFLATED USING A 50/50 CONTRAST FLUID. NEGATIVE PRESSURE WAS APPLIED TO FULLY DEFLATE THE BALLOON, AND AFTER SUFFICIENT TIME, THE DEVICE WAS SUCCESSFULLY WITHDRAWN THROUGH THE SHEATH. NO ISSUES WERE NOTED DURING INFLATION AND NO DAMAGE WAS NOTED TO THE BALLOON CATHETER. THE PROCEDURE WAS COMPLETED USING A NEW EVERCROSS 5X100 PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON. NO PATIENT COMPLICATIONS HAVE BEEN REPORTED AS A RESULT OF THIS EVENT.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 21411421 ↗MalfunctionOct 1, 2020Burst Container or Vessel; Positioning Problem; Burst Container or Vessel; Positioning Problem
PHYSICIAN INTENDED TO USE AN EVERCROSS PTA BALLOON DURING TREATMENT OF A CALCIFIED AND PLAQUE LESION IN THE PATIENT¿S DISTAL COMMON ILIAC ARTERY AND SUPERFICIAL FEMORAL ARTERY. VESSEL DIAMETER IS REPORTED AS 6MM. LESION EXHIBITED 70% STENOSIS. SEVERE VESSEL CALCIFICATION AND TORTUOSITY ARE REPORTED. 3 EVERCROSS PTA BALLOONS ARE REPORTED TO HAVE BEEN USED. NO DAMAGE WAS NOTED TO THE PACKAGING OF ANY OF THE DEVICES, AND NO ISSUES WERE NOTED DURING REMOVAL FROM THE PRODUCT PACKAGING. IFU WAS FOLLOWED AND THE 3 BALLOONS WERE PREPPED WITHOUT ISSUE. A NON-MEDTRONIC INFLATION DEVICE IS REPORTED TO HAVE BEEN USED FOR BALLOON INFLATION. EMBOLIC PROTECTION WAS NOT USED DURING THE PROCEDURE. FOR THE FIRST EVERCROSS BALLOON, IT IS REPORTED THAT NO RESISTANCE WAS ENCOUNTERED DURING ADVANCEMENT AND THE DEVICE WAS NOT PASSED THROUGH A PREVIOUSLY DEPLOYED STENT. A CIRCUMFERENTIAL/RADIAL BALLOON BURST IS REPORTED DURING BALLOON INFLATION AT A PRESSURE OF 15ATM (ABOVE RBP). 4 PRIOR INFLATIONS HAD BEEN APPLIED TO THE DEVICE. THE DEVICE WAS REPLACED. FOR THE SECOND EVERCROSS PTA BALLOON, IT IS REPORTED THAT RESISTANCE WAS ENCOUNTERED DURING ADVANCEMENT AND THE DEVICE WAS NOT PASSED THROUGH A PREVIOUSL
Patient problems: No Clinical Signs, Symptoms or Conditions; No Consequences Or Impact To Patient
MAUDE report 10611676 ↗MalfunctionOct 1, 2020Burst Container or Vessel; Positioning Problem; Burst Container or Vessel; Positioning Problem
PHYSICIAN INTENDED TO USE AN EVERCROSS PTA BALLOON DURING TREATMENT OF A CALCIFIED AND PLAQUE LESION IN THE PATIENT¿S DISTAL COMMON ILIAC ARTERY AND SUPERFICIAL FEMORAL ARTERY. VESSEL DIAMETER IS REPORTED AS 6MM. LESION EXHIBITED 70% STENOSIS. SEVERE VESSEL CALCIFICATION AND TORTUOSITY ARE REPORTED. 3 EVERCROSS PTA BALLOONS ARE REPORTED TO HAVE BEEN USED. NO DAMAGE WAS NOTED TO THE PACKAGING OF ANY OF THE DEVICES, AND NO ISSUES WERE NOTED DURING REMOVAL FROM THE PRODUCT PACKAGING. IFU WAS FOLLOWED AND THE 3 BALLOONS WERE PREPPED WITHOUT ISSUE. A NON-MEDTRONIC INFLATION DEVICE IS REPORTED TO HAVE BEEN USED FOR BALLOON INFLATION. EMBOLIC PROTECTION WAS NOT USED DURING THE PROCEDURE. FOR THE FIRST EVERCROSS BALLOON, IT IS REPORTED THAT NO RESISTANCE WAS ENCOUNTERED DURING ADVANCEMENT AND THE DEVICE WAS NOT PASSED THROUGH A PREVIOUSLY DEPLOYED STENT. A CIRCUMFERENTIAL/RADIAL BALLOON BURST IS REPORTED DURING BALLOON INFLATION AT A PRESSURE OF 15ATM (ABOVE RBP). 4 PRIOR INFLATIONS HAD BEEN APPLIED TO THE DEVICE. THE DEVICE WAS REPLACED. FOR THE SECOND EVERCROSS PTA BALLOON, IT IS REPORTED THAT RESISTANCE WAS ENCOUNTERED DURING ADVANCEMENT AND THE DEVICE WAS NOT PASSED THROUGH A PREVIOUSL
Patient problems: No Clinical Signs, Symptoms or Conditions; No Consequences Or Impact To Patient
MAUDE report 10611667 ↗
Other Catheter, angioplasty, peripheral, transluminal devices
- Coyote™ ES H74939135152010Boston Scientific Corporation · Catheter, angioplasty, peripheral, transluminal879 reports
- Coyote™ ES H74939135204010Boston Scientific Corporation · Catheter, angioplasty, peripheral, transluminal585 reports
- Coyote™ ES H74939135202010Boston Scientific Corporation · Catheter, angioplasty, peripheral, transluminal437 reports
- Coyote™ ES H74939135304010Boston Scientific Corporation · Catheter, angioplasty, peripheral, transluminal384 reports
- Coyote™ ES H74939135404010Boston Scientific Corporation · Catheter, angioplasty, peripheral, transluminal293 reports
- Coyote™ ES H74939134152010Boston Scientific Corporation · Catheter, angioplasty, peripheral, transluminal279 reports
- Coyote™ H74939185202210Boston Scientific Corporation · Catheter, angioplasty, peripheral, transluminal200 reports
- Coyote™ ES H74939135254010Boston Scientific Corporation · Catheter, angioplasty, peripheral, transluminal127 reports
Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.